Galderma Group AG

🇨🇭Switzerland
Ownership
-
Employees
-
Market Cap
$22.9B
Website
http://www.galderma.com/

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance

First Posted Date
2008-06-02
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
243
Registration Number
NCT00687908
Locations
🇵🇷

Galderma Investigational Site, Carolina, Puerto Rico

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

First Posted Date
2008-06-02
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
459
Registration Number
NCT00688064
Locations
🇵🇷

Galderma Investigational Site, Carolina, Puerto Rico

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

First Posted Date
2008-05-05
Last Posted Date
2022-08-23
Lead Sponsor
Galderma R&D
Target Recruit Count
100
Registration Number
NCT00671749
Locations
🇺🇸

Northwest Cutaneous Research Specialists, Portland, Oregon, United States

🇺🇸

Brodell Medical, Warren, Ohio, United States

🇺🇸

Derm Research, P.L.L.C., Louisville, Kentucky, United States

and more 1 locations

An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%

Completed
Conditions
Interventions
First Posted Date
2008-04-29
Last Posted Date
2022-07-29
Lead Sponsor
Galderma R&D
Target Recruit Count
30
Registration Number
NCT00668655
Locations
🇺🇸

Dermatology Consulting Services, High Point, North Carolina, United States

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

First Posted Date
2008-04-29
Last Posted Date
2022-08-23
Lead Sponsor
Galderma R&D
Target Recruit Count
56
Registration Number
NCT00669071
Locations
🇺🇸

Dermatology/Cosmetic Laser Associates of La Jolla, Inc., La Jolla, California, United States

🇺🇸

Tennessee Clinical Research Center, Nashville, Tennessee, United States

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-04-18
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
51
Registration Number
NCT00660985
Locations
🇺🇸

J&S Studies, Inc., College Station, Texas, United States

🇺🇸

DermResearch, Inc., Austin, Texas, United States

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

First Posted Date
2008-04-15
Last Posted Date
2022-08-23
Lead Sponsor
Galderma R&D
Target Recruit Count
305
Registration Number
NCT00658788
Locations
🇺🇸

J&J Studies, Inc, College Station, Texas, United States

🇺🇸

Mount Sinai Department of Dermatology, New York, New York, United States

🇺🇸

Virginia Clinical Research, Inc, Norfolk, Virginia, United States

and more 9 locations

Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage

First Posted Date
2008-03-31
Last Posted Date
2022-08-01
Lead Sponsor
Galderma R&D
Target Recruit Count
30
Registration Number
NCT00647556
Locations
🇺🇸

University of Michigan Department of Dermatology, Ann Arbor, Michigan, United States

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

First Posted Date
2008-01-23
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
1067
Registration Number
NCT00599521
Locations
🇺🇸

East Coast Clinical Research, Inc., Haverhill, Massachusetts, United States

🇺🇸

Dermatology Associates of Rochester, Rochester, New York, United States

🇺🇸

J&S Studies, Inc., Bryan, Texas, United States

and more 30 locations
© Copyright 2024. All Rights Reserved by MedPath